Dosing of Nivolumab in India

H&O What factors determine the appropriate dose of nivolumab? VN The dosing of any drug is determined by multiple factors. Traditionally, drug dosing is initially determined […]

Factors Guiding Selection of Treatment in Metastatic Colorectal Cancer

H&O What factors guide selection of treatment in metastatic colorectal cancer? LS Metastatic colorectal cancer is a very broad area that requires an individualized approach to […]

Serving on the FDA Oncologic Drugs Advisory Committee

H&O What is the role of the Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA)? PH ODAC is one of several […]

Variability in Global Drug Prices

H&O Why are drug prices in the United States so high? ASK Brand-name drug prices are on average approximately 2 to 4 times higher in the […]

Lessons Learned From the Accelerated Approval of Cancer Drugs

H&O What are the principles behind the accelerated approval pathway? BG The US Food and Drug Administration (FDA) introduced the accelerated approval pathway in the 1990s […]

Recent Advances in Understanding Glucocorticoid Receptor Function in Cancer

H&O Are there any new insights into the role of glucocorticoids and/or glucocorticoid receptors? SC There are several new insights into the role of glucocorticoids, […]

The I-SPY Approach to Drug Development

Clinical Advances in Hematology & Oncology October 2016, Volume 14, Issue 10 Laura Esserman, MD, MBA Professor, Departments of Surgery and Radiology Affiliate Faculty, Institute for […]

The Importance of Dose Optimization Prior to Initiation of a Registration Trial

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Nam Atiqur Rahman, PhD Director Division of Clinical Pharmacology V Center for Drug Evaluation […]

Improving Clinical Trial Design Through Quantitative Pharmacology

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Michael L. Maitland, MD, PhD Director of Therapeutics Inova Center for Personalized Health […]

Current Insights Into the Impact of Dihydropyrimidine Dehydrogenase Deficiency in Patients Receiving Treatment With 5-Fluorouracil

Clinical Advances in Hematology & Oncology Volume 14, Issue 7, July 2016 Robert B. Diasio, MD William J. and Charles H. Mayo Professor Director, Mayo Clinic […]

Novel Approaches to Delivering Value in Oncology Drugs

Clinical Advances in Hematology & Oncology April 2016, Volume 14, Issue 4 Steve Miller, MD Senior Vice President & Chief Medical Officer Express Scripts St Louis, […]

The Effect on Drug Development of the National Cancer Institute’s Cancer Therapy Evaluation Program

Clinical Advances in Hematology & Oncology March 2016, Volume 14, Issue 3 James Zwiebel, MD Chief, Investigational Drug Branch Cancer Therapy Evaluation Program National Cancer Institute […]

Casting Doubt on the Scientific Utility of Post-treatment Biopsies in Phase 1 Trials

Clinical Advances in Hematology & Oncology February 2016, Volume 14, Issue 2 Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine Director, Center for Personalized Therapeutics […]

The Impact of Value-Based Insurance Design on Oncology Drugs

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 A. Mark Fendrick, MD Professor, Internal Medicine Director, Center for Value-Based Insurance Design […]

The Current and Future Applications of Immunopharmacogenomics

Clinical Advances in Hematology & Oncology December 2015, Volume 13, Issue 12 Yusuke Nakamura, MD, PhD Professor of Medicine Departments of Medicine and Surgery The University […]

The Benefits and Drawbacks of Biosimilars

Bruce N. Cronstein, MD Professor of Medicine Department of Medicine Department of Biochemistry and Molecular Pharmacology Department of Pathology New York University School of Medicine New […]

The Value and Effectiveness of Angiogenesis Inhibitors for Colorectal Cancer

Alan P. Venook, MD The Madden Family Distinguished Professor of Medical Oncology and Translational Research School of Medicine University of California, San Francisco H&O What […]

Novel Drug Targets in Acute Leukemia

Clinical Advances in Hematology & Oncology August 2015, Volume 13, Issue 8 Wendy Stock, MD Professor Section of Hematology/Oncology Director, Leukemia Program University of Chicago […]

Second-Generation ALK Inhibitors

Clinical Advances in Hematology & Oncology July 2015, Volume 13, Issue 7 Hiroyuki Mano, MD, PhD Professor Department of Cellular Signaling Graduate School of Medicine […]

MET as a Drug Target

Volume 13, Issue 6 June 2015 Ravi Salgia, MD, PhD Professor of Medicine Director, Thoracic Oncology Program Vice Chair, Translational Sciences Department of Medicine, Section of […]